A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of GSK3228836 in Adults With Hepatic Impairment and Healthy Matched Control Participants (B-Assured)
Latest Information Update: 29 Sep 2022
Price :
$35 *
At a glance
- Drugs Bepirovirsen (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Acronyms B-Assured
- Sponsors GlaxoSmithKline; GSK
- 26 Sep 2022 Status changed from recruiting to completed.
- 29 Dec 2021 Planned End Date changed from 13 Jul 2022 to 10 Nov 2022.
- 29 Dec 2021 Planned primary completion date changed from 13 Jul 2022 to 10 Nov 2022.